Atractylenolide I Inhibits EMT and Enhances the Antitumor Effect of Cabozantinib in Prostate Cancer Targeting Hsp27

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Jan 23

PMID 36686743

Authors

Pengfei Qiao

Zhentao Tian

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the effect of Hsp27 and the inhibitory effect of Atractylenolide I (ATL-1) on the proliferation of prostate cancer cell DU145 and PC-3.

Methods: MTT assay was used to detect the inhibitory effect of silencing Hsp27 and ATL-1 on DU145 and PC-3 proliferation of prostate cancer cells. TUNEL detected the apoptosis rate of prostate cancer cell DU145 and PC-3 after silencing Hsp27 and ATL-1 treated. qRT-PCR was used to detect the changes of apoptosis related genes caspase-3, PARP, Bax and Bcl-2 in prostate cancer cell DU145 and PC-3 after the effect of silencing Hsp27 and ATL-1 treated. At the same time, the antitumor effect of ATL-1 combined with cabozantinib was analyzed.

Results: Hsp27 was highly expressed in human prostate cancer. MTT assay showed that ATL-1 inhibited the proliferation of prostate cancer cells DU145 and PC-3 compared with the control group. TUNEL results showed that silencing Hsp27 and ATL-1 treated could significantly promote the apoptosis of prostate cancer cells DU145 and PC-3 compared with the control group. qRT-PCR results showed that compared with the control group, ATL-1 could promote the expression of caspase-3, PARP and Bax in DU145 and PC-3 prostate cancer cells. Inhibition of Hsp27 by ATL-1 reduced cell viability and induced apoptosis. ATL-1 inhibits the antitumor effect of Hsp27 - enhanced cabozantinib. Hsp27 regulates eIF4E and mediates cell protection.

Conclusion: Silencing Hsp27 inhibits EMT. ATL-1 can inhibit the malignant evolution of prostate cancer cells by inhibiting Hsp27/eIF4E. ATL-1 also enhanced chemosensitization of cabozantinib in prostate cancer.

Citing Articles

Atractylenolide I inhibits angiogenesis and reverses sunitinib resistance in clear cell renal cell carcinoma through ATP6V0D2-mediated autophagic degradation of EPAS1/HIF2α.

Li Q, Zeng K, Chen Q, Han C, Wang X, Li B Autophagy. 2024; 21(3):619-638.

PMID: 39477683 PMC: 11849937. DOI: 10.1080/15548627.2024.2421699.

Integrating Chinese medicine into mainstream cancer therapies: a promising future.

Ni B, Xue K, Wang J, Zhou J, Wang L, Wang X Front Oncol. 2024; 14:1412370.

PMID: 38957318 PMC: 11217489. DOI: 10.3389/fonc.2024.1412370.

Triple Silencing of HSP27, cFLIP, and CLU Genes Promotes the Sensitivity of Doxazosin-Induced Apoptosis in PC-3 Prostate Cancer Cells.

Cho J, Sun S, Im E, Yang H, Yoo T Medicines (Basel). 2024; 11(3).

PMID: 38535120 PMC: 10971947. DOI: 10.3390/medicines11030007.

Epithelial-Mesenchymal Transition: A Fundamental Cellular and Microenvironmental Process in Benign and Malignant Prostate Pathologies.

Goncharov A, Vashakidze N, Kharaishvili G Biomedicines. 2024; 12(2).

PMID: 38398019 PMC: 10886988. DOI: 10.3390/biomedicines12020418.

Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation.

Ashrafizadeh M, Zhang W, Tian Y, Sethi G, Zhang X, Qiu A Cancer Metastasis Rev. 2024; 43(1):229-260.

PMID: 38374496 DOI: 10.1007/s10555-024-10168-9.

References

Eto D, Hisaka T, Horiuchi H, Uchida S, Ishikawa H, Kawashima Y . Expression of HSP27 in Hepatocellular Carcinoma. Anticancer Res. 2016; 36(7):3775-9. View

Yang Y, Sun X, Cheng A, Zhang G, Yi H, Sun Y . Increased expression of HSP27 linked to vincristine resistance in human gastric cancer cell line. J Cancer Res Clin Oncol. 2008; 135(2):181-9. DOI: 10.1007/s00432-008-0460-9. View

Cezar-de-Mello P, Vieira A, Nascimento-Silva V, Villela C, Barja-Fidalgo C, Fierro I . ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor. Br J Pharmacol. 2008; 153(5):956-65. PMC: 2267264. DOI: 10.1038/sj.bjp.0707650. View

Sharifi S, Barar J, Hejazi M, Samadi N . Roles of the Bcl-2/Bax ratio, caspase-8 and 9 in resistance of breast cancer cells to paclitaxel. Asian Pac J Cancer Prev. 2014; 15(20):8617-22. DOI: 10.7314/apjcp.2014.15.20.8617. View

Huang J, Zhang G, Shi Y, Zha X, Zhu Y, Wang M . Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway. Sci Rep. 2014; 4:3840. PMC: 3899591. DOI: 10.1038/srep03840. View

Wang S, Fu J, Hao H, Jiao Y, Li P, Han S . Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy. Pharmacol Res. 2021; 170:105728. DOI: 10.1016/j.phrs.2021.105728. View

Gillessen S, Attard G, Beer T, Beltran H, Bjartell A, Bossi A . Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020; 77(4):508-547. DOI: 10.1016/j.eururo.2020.01.012. View

Zhao M, Shen F, Yin Y, Yang Y, Xiang D, Chen Q . Increased expression of heat shock protein 27 correlates with peritoneal metastasis in epithelial ovarian cancer. Reprod Sci. 2012; 19(7):748-53. DOI: 10.1177/1933719111432875. View

Cordonnier T, Bishop J, Shiota M, Nip K, Thaper D, Vahid S . Hsp27 regulates EGF/β-catenin mediated epithelial to mesenchymal transition in prostate cancer. Int J Cancer. 2014; 136(6):E496-507. DOI: 10.1002/ijc.29122. View

10.

Huang H, Lin T, Huang Y, Huang R . Induction of apoptosis and differentiation by atractylenolide-1 isolated from Atractylodes macrocephala in human leukemia cells. Bioorg Med Chem Lett. 2016; 26(8):1905-9. DOI: 10.1016/j.bmcl.2016.03.021. View

11.

Choi S, Kam H, Kim K, Park S, Lee Y . Targeting Heat Shock Protein 27 in Cancer: A Druggable Target for Cancer Treatment?. Cancers (Basel). 2019; 11(8). PMC: 6721579. DOI: 10.3390/cancers11081195. View

12.

Yu L, Yuan X, Wang D, Barakat B, Williams E, Hannigan G . Selective regulation of p38β protein and signaling by integrin-linked kinase mediates bladder cancer cell migration. Oncogene. 2013; 33(6):690-701. DOI: 10.1038/onc.2013.20. View

13.

Konda J, Olivero M, Musiani D, Lamba S, Di Renzo M . Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF. Mol Oncol. 2017; 11(6):599-611. PMC: 5467498. DOI: 10.1002/1878-0261.12042. View

14.

Cory S, Adams J . Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell. 2005; 8(1):5-6. DOI: 10.1016/j.ccr.2005.06.012. View

15.

Yun C, Kim H, Lim J, Lee S . Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy. Cells. 2019; 9(1). PMC: 7017199. DOI: 10.3390/cells9010060. View

16.

Ye Y, Chao X, Wu J, Chi-Yan Cheng B, Su T, Fu X . ERK/GSK3β signaling is involved in atractylenolide I-induced apoptosis and cell cycle arrest in melanoma cells. Oncol Rep. 2015; 34(3):1543-8. DOI: 10.3892/or.2015.4111. View

17.

Mogk A, Ruger-Herreros C, Bukau B . Cellular Functions and Mechanisms of Action of Small Heat Shock Proteins. Annu Rev Microbiol. 2019; 73:89-110. DOI: 10.1146/annurev-micro-020518-115515. View

18.

Shiota M, Bishop J, Nip K, Zardan A, Takeuchi A, Cordonnier T . Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Res. 2013; 73(10):3109-19. DOI: 10.1158/0008-5472.CAN-12-3979. View

19.

Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G . Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle. 2006; 5(22):2592-601. DOI: 10.4161/cc.5.22.3448. View

20.

Wang C, Duan H, He L . Inhibitory effect of atractylenolide I on angiogenesis in chronic inflammation in vivo and in vitro. Eur J Pharmacol. 2009; 612(1-3):143-52. DOI: 10.1016/j.ejphar.2009.04.001. View